Press Releases Bio-Thera Solutions, Ltd.

Equities

688177

CNE100003R98

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 2026-04-20			5-day change	1st Jan Change
22.64 ^CNY	-1.69%		-3.78%	-2.16%

Mar. 23	Bio-Thera Solutions, Ltd. And Intas Pharmaceuticals Ltd Enter Exclusive Commercialization And License Agreement For BAT2506 In India	CI
Feb. 26	Bio-Thera Solutions, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Press Releases

Apr. 01	Accord, Intas, And Bio-Thera File Four IPRs Against Janssen Golimumab Patents	AQ
Mar. 24	Janssen Files BPCIA Complaint Against Bio-Thera And Accord Related To Golimumab Biosimilar	AQ
Mar. 12	Janssen Files BPCIA Complaint Against Bio-Thera And Accord Related To Golimumab Biosimilar	AQ
25-09-04	European Biosimilar Updates – Alvotech/Advanz's MYNZEPLI Approval And Bio-Thera/STADA Tocilizumab Alliance	AQ
25-08-25	Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab	AQ
25-07-17	Bio-Thera Solutions Announces FDA Accepts Biologics License Application for BAT2506, a Proposed Biosimilar to Simponi	AQ
25-04-15	Bio-Thera Solutions Presents Clinical Data for multiple products at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
25-04-02	Organon Acquires TOFIDENCE, a Commercialized Biosimilar to ACTEMRA Injection, for Intravenous Infusion in the U.S.	AQ
25-02-13	Regulatory And Commercial Updates On Bio-Thera's BAT2506 (Golimumab)	AQ
25-02-11	Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi (golimumab), in the United States of America	AQ
25-02-10	Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2506, a Proposed Biosimilar to Simponi, in the European Union	AQ
25-01-15	Bio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorders	AQ
24-12-30	Bio-Thera Solutions Expands Partnership With SteinCares To Market Two Biosimilars In LATAM	AQ
24-11-04	Bio-Thera And Gedeon Richter Reach Exclusive Commercialization Agreement For Ustekinumab Biosimilar	AQ
24-07-26	Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial for BAT3306, a Proposed Biosimilar of Keytruda	AQ
24-07-12	Severe Asthma Pipeline 2024 \| Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera	AQ
24-05-29	Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK	AQ
24-03-26	Bio-Thera Solutions Receives IND Clearance from US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor	AQ
23-12-21	Recent Biosimilar Approvals	AQ
23-10-25	Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litigation in the U.S	AQ
23-07-18	Genentech Files BPCIA Complaint Against Biogen Regarding Tocilizumab	AQ
23-06-16	Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, a Stelara® Biosimilar	BU
23-04-17	Bio-Thera Solutions Announces BAT1006 Poster Presentations at the 2023 AACR Annual Meeting	AQ
23-04-14	Bio-Thera Solutions Announces BAT1006 Poster Presentations at the 2023 AACR Annual Meeting	BU
23-03-13	Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8007, an Antibody-Drug Conjugate Targeting Nectin-4 for the Treatment of Advanced Solid Tumors	BU